EPCAM and breast carcinoma: Promoter hypomethylation of EpCAM leads to its overexpression in various tumors, such as lung cancer [86,87], endometrial cancer [88], breast cancer [89], and ovarian cancer [90], while emphasizing its relevance in OSCC [91].